Pharmacologic development of male hormonal contraceptive agents

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 133-136

  Roth, M Y ^a   Amory, J K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; MALE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ADVERSE OUTCOME; ARTICLE; CONTRACEPTION; HUMAN; POPULATION GROWTH; PRIORITY JOURNAL; SPERMATOGENESIS;

ANIMALS; CONTRACEPTIVE AGENTS, MALE; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; MALE; SPERMATOGENESIS-BLOCKING AGENTS;

EID: 78650514394     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.103     Document Type: Article

References (31)

1. Population Division of the Department of Economic and Social afairs of the United Nations Secretariat. World Population Prospects: The 2008 Revision http://esa.Un.Org/unpp (2008).
2. Godfray, H.C. et al. Food security: the challenge of feeding 9 billion people. Science 327, 812-818 (2010).
3. Henshaw, S.K., Singh, S. & Haas, T. The incidence of abortion worldwide. Int. Fam. Plann. Persp. 25, S30-S38 (1999).
4. Glasier, A.F. et al. Would women trust their partners to use a male pill? Hum. Reprod. 15, 646-649 (2000).
5. Heinemann, K., Saad, F., Wiesemes, M. & Heinemann, L.A. Expectations toward a novel male fertility control method and potential user types: results of a multinational survey. J. Androl. 26, 155-162 (2005).
6. Roth, M.Y. et al. Serum LH correlates highly with intratesticular steroid levels in normal men. J. Androl. 31, 138-145 (2010).
7. Liu, P.Y., Swerdlof, R.S., Christenson, P.D., Handelsman, D.J. & Wang, C. Rate, Extent, And modifers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367, 1412-1420 (2006).
8. Page, S.T., Amory, J.K. & Bremner, W.J. Advances in male contraception. Endocr. Rev. 29, 465-493 (2008).
9. World Health Organization. Contraceptive efcacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril. 65, 821-829 (1996).
10. Nieschlag, E. 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. October 22-23, 2006. Contraception 75, 166-167 (2007).
11. Moreau, C., Trussell, J., Rodriguez, G., Bajos, N. & Bouyer, J. Contraceptive failure rates in France: results from a population-based survey. Hum. Reprod. 22, 2422-2427 (2007).
12. Ly, L.P., Liu, P.Y. & Handelsman, D.J. Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens. Hum. Reprod. 20, 1733-1740 (2005).
13. World Health Organization. Contraceptive efcacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 336, 955-959 (1990).
14. Behre, H.M., Abshagen, K., Oettel, M., Hübler, D. & Nieschlag, E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur. J. Endocrinol. 140, 414-419 (1999).
15. Gu, Y.Q. et al. A multicenter contraceptive efcacy study of injectable testosterone undecanoate in healthy Chinese men. J. Clin. Endocrinol. Metab. 88, 562-568 (2003).
16. Gu, Y. et al. Multicenter contraceptive efcacy trial of injectable testosterone undecanoate in Chinese men. J. Clin. Endocrinol. Metab. 94, 1910-1915 (2009).
17. Turner, L. et al. Contraceptive efcacy of a depot progestin and androgen combination in men. J. Clin. Endocrinol. Metab. 88, 4659-4667 (2003).
18. Kamischke, A. et al. An efective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J. Clin. Endocrinol. Metab. 87, 530-539 (2002).
19. Mommers, E. et al. Male hormonal contraception: a double-blind, Placebo-controlled study. J. Clin. Endocrinol. Metab. 93, 2572-2580 (2008).
20. Qoubaitary, A. et al. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J. Androl. 27, 853-867 (2006).
21. Gu, Y.Q. et al. Male hormonal contraception: efects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men. J. Clin. Endocrinol. Metab. 89, 2254-2262 (2004).
22. Hair, W.M., Kitteridge, K., O'Connor, D.B. & Wu, F.C. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J. Clin. Endocrinol. Metab. 86, 5201-5209 (2001).
23. Steidle, C., Schwartz, S., Jacoby, K., Sebree, T., Smith, T. & Bachand, R. Aa2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. 88, 2673-2681 (2003).
24. Page, S.T. et al. Testosterone gel combined with depomedroxyprogesterone acetate is an efective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J. Clin. Endocrinol. Metab. 91, 4374-4380 (2006).
25. Amory, J.K., Page, S.T., Anawalt, B.D., Matsumoto, A.M. & Bremner, W.J. Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. Contraception 75, 218-223 (2007).
26. Kumar, N., Koide, S.S., Tsong, Y. & Sundaram, K. Nestorone: a progestin with a unique pharmacological profle. Steroids 65, 629-636 (2000).
27. Mahabadi, V. et al. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J. Clin. Endocrinol. Metab. 94, 2313-2320 (2009).
28. Attardi, B.J., Hild, S.A. & Reel, J.R. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 147, 3016-3026 (2006).
29. Hild, S.A., Enbring, J.A., Attardi, B.J., Gropp, D., Koduir, S. & Reel, J.R. Development of dimethandrolone 17B-undecanoate (DMaU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits. Biol. Reprod. 78, 174 (2008).
30. Rosen, J. & Negro-Vilar, A. Novel, Non-steroidal, Selective androgen receptor modulators (SaRMs) with anabolic activity in bone and muscle and improved safety profle. J. Musculoskelet. Neuronal Interact. 2, 222-224 (2002).
31. Chen, J., Hwang, D.J., Bohl, C.E., Miller, D.D. & Dalton, J.T. A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. 312, 546-553 (2005).